HPLC法测定人血浆中伏立康唑及其代谢物的浓度

王志君; 杨云云; 张文静; 王学彬; 宋洪杰; 王卓

doi:10.3969/j.issn.1006-0111.2019.02.012

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

HPLC法测定人血浆中伏立康唑及其代谢物的浓度

王志君, 杨云云, 张文静, 王学彬, 宋洪杰, 王卓

文章导航 > 药学实践与服务 > 2019 > 37(2): 162-165

王志君, 杨云云, 张文静, 王学彬, 宋洪杰, 王卓. HPLC法测定人血浆中伏立康唑及其代谢物的浓度[J]. 药学实践与服务, 2019, 37(2): 162-165. doi: 10.3969/j.issn.1006-0111.2019.02.012

引用本文:

WANG Zhijun, YANG Yunyun, ZHANG Wenjing, WANG Xuebin, SONG Hongjie, WANG Zhuo. Determination of voriconazole and its metabolites in human plasma by HPLC[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(2): 162-165. doi: 10.3969/j.issn.1006-0111.2019.02.012

Citation:

WANG Zhijun, YANG Yunyun, ZHANG Wenjing, WANG Xuebin, SONG Hongjie, WANG Zhuo. Determination of voriconazole and its metabolites in human plasma by HPLC[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(2): 162-165. doi: 10.3969/j.issn.1006-0111.2019.02.012

HPLC法测定人血浆中伏立康唑及其代谢物的浓度

doi: 10.3969/j.issn.1006-0111.2019.02.012

海军军医大学附属长海医院药学部, 上海 200433

Determination of voriconazole and its metabolites in human plasma by HPLC

Department of Pharmacy, Changhai Hospital Affiliated to Naval Medical University, Shanghai 200433

摘要: 目的建立一种快速、灵敏、准确、稳定的测定人血浆中伏立康唑及其代谢物浓度的方法，用于伏立康唑临床治疗药物监测。方法采用高效液相色谱（HPLC）-紫外（UV）检测法，以罂粟碱为内标，乙腈蛋白沉淀法处理血浆样品。色谱柱为ACE5C₁₈-AR （150 mm×4.6 mm），流动相为0.025 mol/L磷酸二氢钠（含三乙胺400 μl/L，用0.25 mol/L的氢氧化钠调至pH=7.0）-乙腈（67：33），流速为l ml/min，柱温为40℃，检测波长为255、276 nm （双波长检测），进样量为20 μl。结果伏立康唑氮氧化物、伏立康唑和罂粟碱的保留时间分别为4.5、11.3、13.7 min；血浆中伏立康唑、伏立康唑氮氧化物线性范围均为0.5~20.0 μg/ml （r=0.999 5），定量下限均为0.5 μg/ml，批内、批间RSD均<11%，定量下限、低、中、高梯度浓度提取回收率在90.3%~109.9%之间。结论该方法操作简便，结果准确，适用于伏立康唑的临床治疗药物监测和对其主要代谢物的测定。
- 伏立康唑 /
- 伏立康唑氮氧化物 /
- 高效液相色谱 /
- 治疗药物监测
Abstract: Objective To establish a HPLC method for the determination of the voriconazole concentration in human plasma,which can be used for voriconazole monitoring clinically. Methods High performance liquid chromatography (HPLC-UV) detection method was used with papaverine as internal standard.Acetonitrile protein precipitation method was employed to treat plasma samples.The chromatographic column was ACE5C₁₈-AR150 mm×4.6 mm with the mobile phase 0.025 mol/L sodium dihydrogen phosphate (containing triethylamine 400 μl/L,pH=7.0 adjusted by 0.25 mol/L sodium hydroxide) - acetonitrile (67∶33).The flow rate was l ml/min,the column temperature at 40 ℃,the detection wavelength at 255,276 nm (double wavelength detection) and sampling amount 20 μl. Results The retention time of voriconazole nitrogen oxide,voriconazole and papaverine were 4.5,11.3 and 13.7 min respectively.The linear ranges of voriconazole and voriconazole nitrogen oxides in plasma were 0.5-20.0 μg/ml (r=0.999 5).The quantitative lower limits were 0.5 μg/ml with RSD< 11%.The recovery rates of extraction were between 90.3% and 109.9%. Conclusion This simple and accurate method is suitable for clinical monitoring of voriconazole.
- voriconazole /
- voriconazole nitrogen oxide /
- HPLC /
- therapeutic drug monitoring

[1]	郭天阳,杜安通,杨雅骊,等.第二代三唑类抗真菌药物的研究进展[J].世界临床药物,2014,35(12):715-718.
[2]	CHUWONGWATTANA S,JANTARAROUNGTONG T,CHITASOMBAT M N,et al.A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis[J].Drug Metab Pharmacokinet,2016,31(2):117-122.
[3]	XU G Q,ZHU L Q,GE T Y,et al.Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp.and Aspergillus spp.in children,adolescents and adults by Monte Carlo simulation[J].Int J Antimicrob Agents,2016,47(6):439-445.
[4]	CABRAL-GALEANO E,RUIZ-CAMPS I,LEN-ABAD O,et al.Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital[J].Enferm Infecc Microbiol Clin,2015,33(5):298-302.
[5]	LI Z W,PENG F H, YAN M,et al.Impact of CYP2C19 genotype and liver function on voriconazole pharmacokinetics in renal transplant recipients[J].Ther Drug Monit,2017,39(4):422-428.
[6]	QI F,ZHU L,LI N,et al.Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole[J].Int J Antimicrob Agents,2017,49(4):403-409.
[7]	WANG Y,WANG T,XIE J,et al. Risk factors for voriconazole-associated hepatotoxicity in patients in the intensive care unit[J].Pharmacotherapy,2016,36(7):757-765.
[8]	BRESSÁN I G,MENDEZ M L,GIMENEZ M I.Validation of a reversed-phase ultra-high-performance liquid chromatographic method with photodiode array detection for the determination of voriconazole in human serum and its application to therapeutic drug monitoring[J].Ther Drug Monit,2018,40(2):276-283.
[9]	LIN S C,LIN S W,CHEN J M,et al.Using sweeping-micellar electrokinetic chromatography to sweeping-micellar electrokinetic[J].Talanta,2010,82(2):653-659.
[10]	PEREA S,PENNICK G J, MODAK A,et al.Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma[J].Antimicrob Agents Chemother,2000,44(5):1209-1213.
[11]	刘学松,何为群,陈文英,等.肺部真菌感染患者伏立康唑血药浓度监测的临床应用[J].国际呼吸杂志,2016,36(20):1521-1526.
[12]	GROLL A H,TOWNSEND R,DESAI A,et al.Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P4503A4[J].Transpl Infect Dis,2017,19(5):e12751.

[1]	陈亭如, 毛士龙. 体内药物分析技术在临床药学工作中的应用进展 . 药学实践与服务, 2024, 42(2): 60-65. doi: 10.12206/j.issn.2097-2024.202305039
[2]	王庆芬, 刘晓玲, 杨育儒, 李杰. 双波长高效液相色谱法同时测定枇芩口服液中7种成分的含量 . 药学实践与服务, 2022, 40(2): 161-164. doi: 10.12206/j.issn.1006-0111.202008007
[3]	桂明珠, 李静, 谢晓恬, 李志玲. 伏立康唑治疗儿童侵袭性真菌感染血药浓度与疗效相关性研究 . 药学实践与服务, 2022, 40(4): 359-363. doi: 10.12206/j.issn.1006-0111.202106075
[4]	王亚妮, 吴迪, 饶志, 李茂星, 葸瑞, 任俊. 异基因造血干细胞移植患者体内环孢素A和伏立康唑的相互作用 . 药学实践与服务, 2022, 40(3): 277-280. doi: 10.12206/j.issn.1006-0111.202111056
[5]	龚亚, 李敏, 曹健, 樊莉. 高效液相色谱法考察8种常用对照品溶液的稳定性 . 药学实践与服务, 2021, 39(5): 426-430. doi: 10.12206/j.issn.1006-0111.202101025
[6]	刘琳琳, 宋洪涛, 严佳. 用UPLC-MS/MS法测定肝功能不全患者血浆中伏立康唑的浓度 . 药学实践与服务, 2021, 39(2): 160-163. doi: 10.12206/j.issn.1006-0111.202008017
[7]	高子昭, 王荣, 赵安鹏. 高原环境影响治疗监测药物代谢的研究进展 . 药学实践与服务, 2020, 38(2): 105-109. doi: 10.3969/j.issn.1006-0111.201912096
[8]	王晶, 张川, 栗意, 任金妹, 唐扣明. 用HPLC法测定丹参素棕榈醇酯脂质体药物含量 . 药学实践与服务, 2019, 37(5): 450-452,480. doi: 10.3969/j.issn.1006-0111.2019.05.012
[9]	杨小英, 张文萍, 王欣瑜, 党宏万. 高效液相色谱荧光法测定血浆中左氧氟沙星的浓度及其生物等效性研究 . 药学实践与服务, 2016, 34(5): 428-430,440. doi: 10.3969/j.issn.1006-0111.2016.05.012
[10]	颜苗, 王柠柠, 李紫薇, 蒋梦飞, 王峰, 张毕奎, 徐萍, 肖轶雯. 伏立康唑血药浓度监测结果评析 . 药学实践与服务, 2016, 34(5): 421-423,446. doi: 10.3969/j.issn.1006-0111.2016.05.010
[11]	彭净, 刘卫. CYP2C19基因多态性对药物代谢影响的研究进展 . 药学实践与服务, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
[12]	刘丽娜, 刘晓东, 肇丽梅. 1例糖尿病合并侵袭性肺曲霉菌感染患者的药学监护 . 药学实践与服务, 2014, 32(5): 389-392. doi: 10.3969/j.issn.1006-0111.2014.05.022
[13]	樊蓉, 党大胜, 赵庆春, 史国兵. 临床药师参与处置伏立康唑致血液系统肿瘤患者视觉障碍的临床实践 . 药学实践与服务, 2013, 31(4): 307-309. doi: 10.3969/j.issn.1006-0111.2013.04.020
[14]	姜韧, 刘刚, 张华, 常华, 谭生建. 高效液相色谱法测定小儿润肺口服液中黄芩苷含量 . 药学实践与服务, 2008, (6): 435-437.
[15]	王敬国, 王晓波, 袭荣刚. 药物流行病学研究在我院的开展与思考 . 药学实践与服务, 2002, (4): 253-255.
[16]	张治然, 王晓波, 孙辉. 我院治疗药物监测的开展与结果分析 . 药学实践与服务, 2002, (1): 26-28.
[17]	马骏, 谢景文, 孙卫胜, 谢华, 贾正平, 刘静. 治疗药物监测进展 . 药学实践与服务, 2000, (4): 250-254,244.
[18]	孙成春, 王景祥. 开展治疗药物监测的体会 . 药学实践与服务, 1998, (5): 304-306.
[19]	杨丽英, 李景玉, 卢清林, 李红宇. 高效液相色谱法监测血清中卡马西平血药浓度50例分析 . 药学实践与服务, 1997, (2): 99-100.
[20]	王卓, 刘荔荔, 高申, 吴玉田. 柱切换高效液相技术及其在复杂样品分析中的应用 . 药学实践与服务, 1996, (6): 349-354.

点击查看大图

计量

文章访问数: 2496
HTML全文浏览量: 284
PDF下载量: 370
被引次数: 0

HPLC法测定人血浆中伏立康唑及其代谢物的浓度

doi: 10.3969/j.issn.1006-0111.2019.02.012

海军军医大学附属长海医院药学部, 上海 200433

收稿日期: 2018-08-03
修回日期: 2018-11-30

关键词:

摘要: 目的建立一种快速、灵敏、准确、稳定的测定人血浆中伏立康唑及其代谢物浓度的方法，用于伏立康唑临床治疗药物监测。方法采用高效液相色谱（HPLC）-紫外（UV）检测法，以罂粟碱为内标，乙腈蛋白沉淀法处理血浆样品。色谱柱为ACE5C₁₈-AR （150 mm×4.6 mm），流动相为0.025 mol/L磷酸二氢钠（含三乙胺400 μl/L，用0.25 mol/L的氢氧化钠调至pH=7.0）-乙腈（67：33），流速为l ml/min，柱温为40℃，检测波长为255、276 nm （双波长检测），进样量为20 μl。结果伏立康唑氮氧化物、伏立康唑和罂粟碱的保留时间分别为4.5、11.3、13.7 min；血浆中伏立康唑、伏立康唑氮氧化物线性范围均为0.5~20.0 μg/ml （r=0.999 5），定量下限均为0.5 μg/ml，批内、批间RSD均<11%，定量下限、低、中、高梯度浓度提取回收率在90.3%~109.9%之间。结论该方法操作简便，结果准确，适用于伏立康唑的临床治疗药物监测和对其主要代谢物的测定。

English Abstract

Determination of voriconazole and its metabolites in human plasma by HPLC

Department of Pharmacy, Changhai Hospital Affiliated to Naval Medical University, Shanghai 200433

Received Date: 2018-08-03
Rev Recd Date: 2018-11-30

Keywords:

Abstract: Objective To establish a HPLC method for the determination of the voriconazole concentration in human plasma,which can be used for voriconazole monitoring clinically. Methods High performance liquid chromatography (HPLC-UV) detection method was used with papaverine as internal standard.Acetonitrile protein precipitation method was employed to treat plasma samples.The chromatographic column was ACE5C₁₈-AR150 mm×4.6 mm with the mobile phase 0.025 mol/L sodium dihydrogen phosphate (containing triethylamine 400 μl/L,pH=7.0 adjusted by 0.25 mol/L sodium hydroxide) - acetonitrile (67∶33).The flow rate was l ml/min,the column temperature at 40 ℃,the detection wavelength at 255,276 nm (double wavelength detection) and sampling amount 20 μl. Results The retention time of voriconazole nitrogen oxide,voriconazole and papaverine were 4.5,11.3 and 13.7 min respectively.The linear ranges of voriconazole and voriconazole nitrogen oxides in plasma were 0.5-20.0 μg/ml (r=0.999 5).The quantitative lower limits were 0.5 μg/ml with RSD< 11%.The recovery rates of extraction were between 90.3% and 109.9%. Conclusion This simple and accurate method is suitable for clinical monitoring of voriconazole.